Method for light-emitting diode phototherapy in chronic nasal polyposis
SUBSTANCE: preliminary interstitial laser-induced heat treatment with high-energy laser beam covering nasal polyp tissue is followed by introducing 1% emoxipine in an amount up to 1.0 ml into a polyp stroma. A distal end of a flexible light pipe of AFS/Z light-emitting-diode therapy apparatus emitting visible green light is brought to the polyp. A light power is 60 mW/cm2; a spot diameter is up to 2 cm. The polyp is illuminated for 5 minutes daily for 7 days.
EFFECT: method enables accelerating the process of nasal polyp tissue shrinking and necrotising tissue rejection that is ensured by fast accumulation of an antioxidant in the polyp stroma induced by the phototherapy, lipid peroxidation suppression, and improved antioxidant tissue protection.
2 tbl, 1 ex
FIELD: medicine, pharmaceutics.
SUBSTANCE: invention refers to pharmaceutical industry, namely to selenium nanocomposites of natural hepatotrophic galactose-containing polysaccharide matrixes, representing water-soluble orange-red powders containing zerovalent selenium (Se0) nanoparticles sized 1-100 nm in the quantitative content of 0.5 - 60 wt %, possessing antioxidant activity for treating and preventing redox-related pathologies, particularly for treating toxic liver damage, to a method for producing and to an antioxidant agent containing the above nanocomposites.
EFFECT: invention provides the targeted agent delivery to liver cells, as well as higher agent accessibility and lower toxic action of selenium.
7 cl, 11 ex, 4 tbl
SUBSTANCE: method involves chelation of ferric (III) ions both in vivo, and in vitro with using 2-ethyl-6-methyl-3-hydroxypyridine succinate (Mexidol) to produce a stable stained complex having a high molecular weight and a complex (organic-inorganic) composition not identified among the known compounds.
EFFECT: high effectiveness of the chelation process and low toxicity of Mexidol that makes it promising for biomedical application.
4 dwg, 3 tbl, 3 ex
SUBSTANCE: invention relates to field of organic chemistry, namely to novel compound - 5(6)-nitro-1-(thietanyl-3)-2-ethoxybenzimidazole, inhibiting peroxidation of lipids.
EFFECT: novel compound, possessing useful biological properties, has been obtained.
2 cl, 1 dwg, 2 ex
SUBSTANCE: invention represents a mixture of two structural isomers: 2,6-di(1,7,7-trimethylbicyclo[2.2.1]hept-2-yl)-4-methylphenol and its diastereomers, and 2-(1,7,7-trimethylbicyclo[2.2.1]hept-2-yl)-6-(2,2,1-trimethylbicyclo[2.2.1]hept-5-yl)-4-methylphenol, and their diastereomers with the ratio of the first and second structural isomer isomers from 60:40 wt % to 95:5 wt %.
EFFECT: extension of the arsenal of means, possessing simultaneously haemorheological, anti-aggregate, anti-thrombogenic, retinoprotecting, endothelium-protecting, neuroprotecting, anti-arrhythmia and anti-ischemic activity, enhancing the cerebral blood flow.
4 dwg, 20 tbl, 6 ex
SUBSTANCE: what is presented is using Histochrom (same as echinochrome A or pentahydroxyethyl naphthoquinone) as an agent able to prevent pulmonary fibrosis developed under cytostatic agents. The invention can be used for the pharmacological prevention and correction of the pulmonary tissue disorders caused by administering the cytostatic agents.
EFFECT: preventing hypertrophy of interalveolar connective tissue in the lungs associated with administering bleomycin.
4 dwg, 1 tbl
SUBSTANCE: drops possessing antiviral and immunomodulatory effects characterised by the fact that they represent a 95% ethanol infusion of wild strawberry leaves and fruit specified in: red raspberry fruit, mountain ash fruit, bilberry fruit, blood-red hawthorn fruit, cinnamon rose fruit; 15-25 mg of the substance in 1 ml of the infusion.
EFFECT: drops possess pronounced antiviral and immunomodulatory effects.
15 tbl, 5 ex
SUBSTANCE: melanin having water-solubility of at least 80% and an paramagnetic centre concentration of at least 8·1017 spin/g is administered orally into the animals having been exposed to the radiation in a dose high enough to cause a spinal radiation injury; melanin is administered after dissolved in distilled water in the effective concentration. Melanin water is used as drinking water for the mice having been exposed to single and fractionated acute radiation, which is able to cause acute radiation disease. Melanin water is taken from the 1st to 30th day following the single radiation, or from the 1st day of the fractionated radiation to the 30th day on completion of the radiation.
EFFECT: higher survival rate, faster recovered haemopoiesis, body weight and orientation and motion activity.
7 tbl, 5 ex
SUBSTANCE: invention provides a composition having antioxidant properties in the form of a tablet, comprising an active agent based on nicotinamide adenine dinucleotide in reduced form (NADH) and inert filling agents, characterised by that the active ingredient is a complex which is a mixture of 10 wt % NADH with 63 wt % vegetable fats, 17 wt % beeswax and 10 wt % chlorophyll, and the inert filling agents are in the form of microcrystalline cellulose, Macrogol 6000, intense sweetener and a food flavourant.
EFFECT: invention provides a new tablet form of NADH.
SUBSTANCE: invention refers to a pharmaceutical composition with anti-ischemic and antioxidant activity in the form of tablets or capsules, and a method for preparing it. The composition contains 4-((3-oxo-3-ethoxypropanoyl)amino)benzoic acid in an amount of 40 to 80 wt %, an amino-containing compound and pharmaceutically acceptable excipients. The amino-containing compound is specified in a group of trometamol, methyl glucamine and L-lysine; 1 mole of 4-((3-oxo-3-ethoxypropanoyl)amino)benzoic acid is accounted for 0.05 to 0.25 mole of the above amino-containing compound. The composition also contains lactose, microcrystalline cellulose, calcium stearate and other pharmaceutically acceptable excipients. According to the method for preparing the composition, taking 4-((3-oxo-3-ethoxypropanoyl)amino)benzoic acid and amino-containing compound in molar ratio 1:0.05 to 1:0.25, pre-mixing, moisturising with a aqueous or alcohol solution of a binding agent, adding pharmaceutically acceptable excipients in such an amount to provide the content of 4-((3-oxo-3-ethoxypropanoyl)amino)benzoic acid from 40 to 80 wt %, granulating the mixture, drying and producing tablets or capsules according to the known technique.
EFFECT: implementing the above application.
6 cl, 7 tbl, 4 ex
SUBSTANCE: claimed is the application of 5(6)-nitro-1-(1,1-dioxothietanyl-3)-2-chlorobenzimidazole of formula (I) , earlier known as the means with broncholytic and spasmolytic activity, as the means, inhibiting peroxide oxidation of lipids.
EFFECT: realisation of the claimed purpose.
SUBSTANCE: device for the endoluminal treatment of a blood vessel comprises a flexible wave guide with a light guide tube. The wave guide has an elongated axis, a proximal end with a connector for optical connection to a laser light source, a distal end placed in the blood vessel and comprising an emitting surface for the emission of light from the light source sideways in relation to the elongated axis of the wave guide onto a surrounding vascular wall segment extending within the angular range. The device is provided with a secondary laser light source, a reflected light reception detector, a laser light transparent cone-shaped primary diffuser (1) with laser light deflection and a secondary diffuser (3) extending the laser light coverage area. The primary diffuser (1) is mounted at an optical output of the wave guide between the emitting surface of the wave guide and a sapphire safety cap (2). The secondary diffuser (3) is mounted between the safety cap (2) and the primary diffuser (1). The device also comprises a detachable sterilised protective sheath (4). The protective sheath (4) is made from heat-shrinkage polytetrafluoroethylene, configured as a tube with an ultrasound contrast insert and mounted on the wave guide over the safety cap (2).
EFFECT: using the invention is expected to improve the quality of blood vessel coagulation, eliminating light guide burning and reducing its friction on the blood vessel.
2 cl, 3 dwg
SUBSTANCE: method involves a drug-induced correction of the gastric secretion, a bile-expelling and antihelicobacter therapy. An epigastric region, and then a projection of a gall bladder are exposed to a red narrow-band optical emission generated by a light-emitting diode. The exposure is continuous, and lasts for 4-5 min per each region. A wave length is 650 nm at an emissive power of 100% generated by Spectrum LC apparatus. The technique is stable. The therapeutic course is 8-10 procedures conducted daily or every second day.
EFFECT: relieving clinical manifestations of the disease, normalising the gastric or duodenal mucosa ensured by the anti-inflammatory effect of the red emission generated by the light-emitting diode.
1 tbl, 1 ex
SUBSTANCE: photochromotherapy is carried out at the background of the drug correction of an increased secretory function of the stomach. The epigastric area, then the bile bladder projection area is exposed to green narrow-band light-diode radiation. The influence is performed in a continuous mode of 4-5 min on each area. The wavelength is 540 nm with the level of radiation power of 100% of the "Spectr-LTS" apparatus. The methodology is stable. The course of treatment includes 8-10 procedures, carried out daily or every second day.
EFFECT: relief of pain, dyspeptic, astenovegetative syndromes, normalisation of the stomach and duodenum mucosa, increased efficiency of eradication drug therapy.
1 tbl, 1 ex
SUBSTANCE: patient is anaesthetised. The dental deposit is removed. A filling material colour is chosen. A tooth decay cavity is prepared, disinfected, washed with water, desalivated and dried. The cavity walls and bottom are wetted with Gluftored liquid on an applicator, exposed to a blue light emitting diode for 30 seconds passing through a ring magnet tip; the cavity is dried. The cavity bottom is wetted with a suspension applied on the applicator and activated with the blue light emitting diode with a magnetic tip for 30 sec, and dried. The total exposure is 60 seconds. An etching solution for total etching is administered into the cavity, washed out; the cavity is dried; an adhesive is administered, inflated with air, exposed to a blue light polymerisation activator for 20 sec. The decay cavity is filled by introducing the filling material in layers and exposed to the blue light polymerisation activator for 20 seconds. The filling is polished with final light exposure. The patient is advised to follow oral hygiene and given reasons for using Mexidol dent Calcium toothpaste.
EFFECT: method provides preventing post-therapeutic complications and increases clinical effectiveness.
5 dwg, 1 ex
SUBSTANCE: opening of a carious cavity, ablation of overhanging enamel edges on the entire circumference, necrectomy and drug treatment with a 0.06% chlorhexidine solution are performed. The preparation "Lemifaren" is applied on walls and bottom of the carious cavity in a uniform 1 mm thick layer, which is left for 1 day under temporary filling. After the removal of the preparation irradiation in a pulse mode with the power of 5 W and frequency of 2000-3000 Hz is carried out for 5 min with the application of the laser apparatus ALST-01. After that, the cavity is restored with an account of functional and aesthetic parameters of the particular tooth.
EFFECT: effective treatment of deep caries prevents caries recurrences and pulp inflammation.
SUBSTANCE: method involves removing an epithelial layer, exposing a cornea by saturating it through multiple instillations of 0.1% riboflavin followed by the ultraviolet exposure. After the epithelial layer has been removed, a ring made of an ultraviolet-protected contact lens is applied on a surface of the eyeball perilimbally. An outer diameter of the ring covers the limb by no more than 2 mm, whereas an inner diameter of the ring is equal to a basic diameter of the keratoconus. The whole duration of the ultraviolet exposure involves additional instillations of riboflavin on the cornea every 3-4 minutes. The exposure is characterised by wavelength 365 nm, power 3.0 mWt/cm2 at 50 mm for 30 minutes with the ring to be removed after the exposure is completed.
EFFECT: method is easy to implement, involves no difficulties for specialists, providing higher clinical effectiveness by limiting the ultraviolet exposure area, preventing the ultraviolet involvement of the limb and reducing a risk of postoperative complications.
SUBSTANCE: transurethral bladder resection enables the exposure of tumour bed tissues to pulse laser light of wave length 970 nm and emitting power from 10 to 15 Wt. The exposure involves contacting a light guide to bladder wall wound tissues until visualising the coagulation changed within the contact exposure. That is combined with advancing the light guide spirally from the wound periphery to the tumour bed centre. A method involves improving the therapeutic effect by preventing the tumour recurrences, preventing erythrocyturia and developing complications caused by intraoperative complications, as well as preventing complications caused by the deep thermal exposure on the bladder wall.
EFFECT: improving the oncologic surgical effect is ensured by eliminating the tumour cell migration along the tumour bed vessels by the primary coagulation of the peripheral sections of the treated bed.
3 cl, 3 ex
SUBSTANCE: method relates to physiotherapy, namely to phototherapy, and can be used in the prevention and treatment of a series of human and animal diseases. Irradiation of a patient's body surface by light pulses in the ultraviolet range is carried out. The irradiation is carried out by the pulses, duration of which is not shorter than 10-10 s and not longer than 5×10-3 s. The irradiation in red and infrared spectrum ranges is carried out simultaneously with the ultraviolet irradiation, with the ratio of values of irradiancy in the said three sections constituting in fractions, 97:1.5:1.5.
EFFECT: method makes it possible to increase the efficiency and safety of the procedure due to the change of boundaries of the range of the radiation pulse duration; boundaries of the spectral range of the irradiation and the ratio of spectral radiation sections.
14 cl, 2 dwg
SUBSTANCE: invention refers to medicine, namely to rheumatology, and can be used in treating patients suffering from rheumatoid arthritis. The method involves prescribing methotrexat 15 mg a week per os, folic acid 5 mg a week per os, movalis 15 mg a day per os. If the patient has the second degree of activity of rheumatoid arthritis, IL-1β of 1.3±0.3 pg/ml and more, IL-6 of 1.5±0.3 pg/ml and more, TNF-α of 1.78±0.35 pg/ml and more, IL-4 of 3.7±0.34 pg/ml and less, leptine of 6.4±0.42 pg/ml and more, glycosaminoglycans of 0.310±0.032 g/l, 7 daily procedures of intravenous laser exposure are prescribed. The KL-VLOK radiation head with a wavelength of 635 nm, disposable light guide tip power of 1.5 mW, exposure time of 15 minutes is alternated every second day with the KL-VLOK-365 laser head for UV blood exposure with a wavelength of 365 nm, light guide tip power of 1.0 mW and exposure time of 5 minutes. If observing the third degree of activity, IL-1β of 2.01±0.18 pg/ml and more, IL-6 of 3.01±0.38 pg/ml and more, TNF-α of 3.3±0.25 pg/ml and more, IL-4 of 1.3±0.24 pg/ml and less, leptine of 8.8±0.72 pg/ml and more, glycosaminoglycans of 1.3±0.54 g/l, 10 daily procedures are performed. The KL-VLOK radiation head with a wavelength of 635 nm, disposable light guide tip power of 1.5-2.0 mW, exposure time of 15 minutes is alternated every second day with the KL-VLOK-365 laser head for UV blood exposure with a wavelength of 365 nm, light guide tip power of 1.0 mW and exposure time of 5 minutes.
EFFECT: method enables reducing a rate of aggravations, an intensity of clinical manifestations, drug load on the patient, prolonging remissions ensured by a normalising effect on cytokine dynamics - reduced pro-inflammatory and increased anti-inflammatory cytokines.
SUBSTANCE: invention refers to medicine, namely to therapeutic dentistry, and can be used for the local treatment of chronic gingivitis caused by tobacco smoking in young individuals. That is ensured by a preparatory procedure of luminal-dependent chemiluminescence of the oral fluid aiming at a maximum burst and a glow light sum. If the maximum burst falls within the range of 3.3 to 18.15 standard units, whereas the glow light sum ranges from 8.2 to 40 standard units, an antioxidant therapy is conducted by using a transverse gingival mucosa electrophoresis on 5% aqueous propolis by means of jaw electrodes in a tray at a current intensity of 0.5-1 mA and an exposure of 8-10 minutes. A polarity is alternated with a positive pole to be taken the first. The therapeutic course makes 4 procedures every second day. Colgate Propolis Toothpase and Mouthwash are used additionally during 30 days. If the maximum burst is from 0.8 to 1.24 standard units, whereas the glow light sum ranges from 3.34 to 7.5 standard units, a pro-oxidant therapy is required by using an exposure to magnetic infrared laser (MIL) light covering a projection of gums and generated by Optodan laser with a periodontal attachment The exposure parameters: 2-2,000 Hz in segments, 2 minutes per each segment, no more than 12 minutes per 1 procedure. The therapeutic course makes 4 procedures every second day. Parodontax Toothpase and Mouthwash are used additionally during 12 days.
EFFECT: method simplifies and reduces the length of the treatment in the given category of patients.
FIELD: medicine, pharmaceutics.
SUBSTANCE: invention refers to organic chemistry, namely to benzimidazole-4-carboxamide derivatives of formula , wherein X means an alkenyl group C2-C7 substituted by two methyls, nitro-radical mono-substituted thienyl, unsubstituted quinolinyl, unsubstituted indolyl, unsubstituted pyridazinyl, unsubstituted piperazinyl, C1-C6-alkyl disubstituted piperazinyl, unsubstituted piperidinyl, unsubstituted pyrazinyl, unsubstituted imidazolyl, unsubstituted pyrimidinyl, phenyl monosubstituted pyrimidinyl, pyrimidinyl disubstituted by an amine radical and a radical specified in a group containing -F, -Cl, -Br or -I, hydroxyl trisubstituted phenyl, methoxy-radical trisubstituted phenyl, hydroxyl and methoxy-radical disubstituted phenyl, pyrazolyl disubstituted by a radical specified in a group containing a C1-C6-alkyl, and by a radical specified in a group containing -F, -C1, -Br or -I; Y means aminophenyl monosubstituted by a radical of -F, -O, -Br or -I phenyl, hydroxyethyl disubstituted by hydroxymethyl or C1-C6-alkyl and phenyl monosubstituted by a nitro group, an amino group or a halogen atom; Y also means unsubstituted piperazinyl, unsubstituted pyridyl, unsubstituted pyrazinyl, C1-C6-alkyl monosubstituted thiazol, unsubstituted pyrimidinyl, unsubstituted purinyl. The invention also refers to a pharmaceutical composition based on the compound of formula (I), using the compound of formula (I), a method for producing the compound of formula (I).
EFFECT: there are prepared new benzimidazol-4-carboxamide derivatives possessing antiviral activity.
5 cl, 6 dwg, 4 tbl, 688 ex